Biotech Values

[DewDiligence]

ESRX—There nothing about “indefinitely” in this article, but I wouldn't find it hard to swallow if you consider the pricing structure of drugs.

While the article didn’t use the word indefinitely, the phrase “next several years” without qualification sounds rather indefinite.

In any case, I’m bearish on the prospects for such PBMs as CVS and ESRX. These companies have made an enormous amount of money for themselves but, as far as I can tell, they haven’t done squat for reducing costs of the US healthcare system as a whole. Sooner or later, the PBM business model is destined to be tarnished as the US moves ever closer to the way drugs are priced in the rest of the world.